Team

Scientific advisory board

RHI CSO
DR. HINRICH STAECKER

MD. PHD

RHI Chief Scientific Officer 
and University of Kansas Medical Leader and Visionary. Dr. Staecker created the first and only gene therapy for hearing loss approved for human clinical trials (Novartis CGF166).


DR. XUE ZHONG LIU

MD. PHD

RHI Scientific Advisor and decorated Surgeon at the University of Miami. Dr. Liu’s expertise in identifying the genetic causes of hearing loss is unparalleled; as one of the top NIH-funded Otolaryngologists.


DR. ZHENG-YI CHEN

D. PHIL

RHI Scientific Advisor joining us from the World-renowned Massachusetts Eye and Ear Infirmary research center at  the Harvard Medical School. Dr. Chen’s lab was responsible for generating RHI100’s groundbreaking POC data.


DR. JEFFREY HOLT

PHD

RHI Scientific Advisor from Boston Children’s Hospital at Harvard’s Medical School. Dr. Holt brings expertise in developing vector constructs for the delivery of gene therapies to the inner ear.


Dr. Athanasia Warnecke

MD. PHD

RHI Scientific Advisor having attended the Hannover Medical School with expertise in presenting human-clinical-trial briefing packages to the Paul-Ehrlich Institute (PEI).

Business Advisors


DR. LEE GOLDEN

An MD Clinical Trial design and Drug Development Specialist bringing over 20+ years of experience in all phases of drug development. Currently the Head of Global Clinical Development at PTC Therapeutics


ANDREW KOOPMAN

Investor Relations and Business Development of more than 30 years in the Biotechnology and Biomedical industries.